View Single Post
Old 06-03-2022, 02:55 PM
agate's Avatar
agate agate is offline
Member
 
Join Date: Aug 2006
Location: Wild West
Posts: 918
15 yr Member
agate agate is offline
Member
agate's Avatar
 
Join Date: Aug 2006
Location: Wild West
Posts: 918
My Mood:
15 yr Member
Arrow (MSAA) What's new in MS research (May 2022)

From the MSAA, "What's New in MS Research - May 2022":

What’s New in MS Research - May 2022 | MSAA

One of the articles may be noteworthy as it includes this:

Quote:
People receiving Ocrevus® (ocrelizumab) faced a 2.18 greater risk of developing COVID-19 post-vaccination relative to the general population, while those taking beta-interferon DMTs and glatiramer acetate (marketed as Copaxone® and by other names) had a lower risk than the general population. The post-vaccination risk of infection compared to that of the general population for people on other DMTs was:

Aubagio® (teriflunomide): 1.04
Mavenclad® (cladribine): 1.21
Tysabri (natalizumab): 1.22
Tecfidera® (dimethyl fumarate): 1.34
Gilenya® (fingolimod): 1.63

The investigators arrived at their findings by examining data on all 42,402 people in England who are receiving DMTs for treatment of MS. They found that more than 28,000 of those people had been tested for COVID-19, with 4,104 testing positive for coronavirus.
[Emphasis added]
__________________
Repeal the law of gravity!

MS diagnosed 1980. Type 2 diabetes, osteoarthritis.
Avonex 2002-2005. Copaxone 6/4/07-5/15/10. Currently: Glatopa (generic Copaxone), 40mg 3 times/week, since 12/16/20
agate is offline   Reply With QuoteReply With Quote